- Avalo Therapeutics reported approximately **$112 million** in cash, cash equivalents, and short-term investments as of **September 30, 2025**, providing an expected cash runway **into 2028**.  **[1534120_0001534120-25-000011_ex-991avalocorporatepres.htm:6]** **[1534120_0001534120-25-000011_ex-991avalocorporatepres.htm:0]** 
- The company's lead asset, **AVTX-009**, an anti-IL-1β monoclonal antibody, is currently in a Phase 2 LOTUS trial for Hidradenitis Suppurativa (HS), with **topline data expected mid-2026**.  **[1534120_0001534120-25-000011_ex-991avalocorporatepres.htm:0]** **[1534120_0001534120-25-000011_ex-991avalocorporatepres.htm:5]**  
- AVTX-009 is positioned to address the HS market, which is projected to grow to **>$10 billion by 2035**, offering potential advantages over existing therapies with **15x higher affinity** and a longer half-life than lutikizumab.  **[1534120_0001534120-25-000011_ex-991avalocorporatepres.htm:0]** **[1534120_0001534120-25-000011_ex-991avalocorporatepres.htm:4]** **[1534120_0001534120-25-000011_ex-991avalocorporatepres.htm:5]** 
- As of September 30, 2025, Avalo Therapeutics had **17.8 million** common shares outstanding and an adjusted market capitalization of **$472.7 million** based on a stock price of **$12.71**.  **[1534120_0001534120-25-000011_ex-991avalocorporatepres.htm:6]**

Avalo Therapeutics provides Q3 2025 investor presentation update

- Avalo Therapeutics (AVTX) is advancing **AVTX-009**, an IL-1β antibody, in a **Phase 2b clinical trial for hidradenitis suppurativa (HS)**.  **[1534120_2144500_0]** 
- The company anticipates **full enrollment of the Phase 2b trial by the end of 2025** and expects **topline data by mid-2026**.  **[1534120_2144500_0]** **[1534120_2144500_2]** 
- AVTX-009 is positioned for **higher efficacy** and a **more favorable dosing regimen** in HS compared to existing treatments, attributed to its specific IL-1β targeting, higher affinity, and longer half-life.  **[1534120_2144500_1]** **[1534120_2144500_2]** 
- Avalo Therapeutics reported a **cash balance of $125 million**, providing a **cash runway into 2028** and covering the Phase 2 data readout.  **[1534120_2144500_4]**